TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
TG Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 17.1%. For fiscal 2025 it was 20.0%, against 12.7% the year before. The highest annual figure on record is 20.0% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.0% | +7.3 |
| FY2024 | Dec 31, 2024 | 12.7% | +3.9 |
| FY2023 | Dec 31, 2023 | 8.8% | +7847.8 |
| FY2022 | Dec 31, 2022 | -7839.0% | −2684.7 |
| FY2021 | Dec 31, 2021 | -5154.3% | +174841.8 |
| FY2020 | Dec 31, 2020 | -179996.1% | −68775.7 |
| FY2019 | Dec 31, 2019 | -111220.4% | +3516.4 |
| FY2018 | Dec 31, 2018 | -114736.8% | −36636.8 |
| FY2017 | Dec 31, 2017 | -78100.0% | −26146.7 |
| FY2016 | Dec 31, 2016 | -51953.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 9.0% | −15.7 |
| Q1 FY2026 | Mar 31, 2026 | 17.0% | +9.8 |
| Q4 FY2025 | Dec 31, 2025 | 26.2% | −1.5 |
| Q3 FY2025 | Sep 30, 2025 | 18.2% | +3.3 |
| Q2 FY2025 | Jun 30, 2025 | 24.7% | +12.7 |
| Q1 FY2025 | Mar 31, 2025 | 7.1% | +21.7 |
| Q4 FY2024 | Dec 31, 2024 | 27.7% | +56.1 |
| Q3 FY2024 | Sep 30, 2024 | 14.8% | −54.4 |
| Q2 FY2024 | Jun 30, 2024 | 12.0% | +289.9 |
| Q1 FY2024 | Mar 31, 2024 | -14.6% | +459.5 |
| Q4 FY2023 | Dec 31, 2023 | -28.4% | +96895.4 |
| Q3 FY2023 | Sep 30, 2023 | 69.2% | +37263.9 |
| Q2 FY2023 | Jun 30, 2023 | -277.9% | +6277.8 |
| Q1 FY2023 | Mar 31, 2023 | -474.1% | +2843.0 |
| Q4 FY2022 | Dec 31, 2022 | -96923.8% | −92919.1 |
| Q3 FY2022 | Sep 30, 2022 | -37194.7% | −33001.2 |
| Q2 FY2022 | Jun 30, 2022 | -6555.7% | −1540.1 |
| Q1 FY2022 | Mar 31, 2022 | -3317.1% | +7931.6 |
| Q4 FY2021 | Dec 31, 2021 | -4004.6% | +224369.1 |
| Q3 FY2021 | Sep 30, 2021 | -4193.5% | +221390.7 |
| Q2 FY2021 | Jun 30, 2021 | -5015.7% | +128787.0 |
| Q1 FY2021 | Mar 31, 2021 | -11248.7% | +120975.0 |
| Q4 FY2020 | Dec 31, 2020 | -228373.7% | −128476.3 |
| Q3 FY2020 | Sep 30, 2020 | -225584.2% | −65423.7 |
| Q2 FY2020 | Jun 30, 2020 | -133802.6% | −40265.8 |
| Q1 FY2020 | Mar 31, 2020 | -132223.7% | −40936.8 |
| Q4 FY2019 | Dec 31, 2019 | -99897.4% | +42602.6 |
| Q3 FY2019 | Sep 30, 2019 | -160160.5% | −69823.7 |
| Q2 FY2019 | Jun 30, 2019 | -93536.8% | −210234.2 |
| Q1 FY2019 | Mar 31, 2019 | -91286.8% | +18126.3 |
| Q4 FY2018 | Dec 31, 2018 | -142500.0% | −60828.9 |
| Q3 FY2018 | Sep 30, 2018 | -90336.8% | −7218.4 |
| Q2 FY2018 | Jun 30, 2018 | 116697.4% | +191500.0 |
| Q1 FY2018 | Mar 31, 2018 | -109413.2% | – |
| Q4 FY2017 | Dec 31, 2017 | -81671.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -83118.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -74802.6% | – |
See a number that looks wrong?